Clinical Trial Search

Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD…

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.54; -0.57; -0.62 percentage of glycosylated haemoglobin

Primary: Number of Subjects With Inhibitory Anti-C1-esterase-inhibitor Antibodies — 0 subjects

Primary: Percentage of Participants With Complete Cytogenetic Response (CCyR) — 50.0; 42.1 Percentage of participants — p=0.3106

Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Daclatasvir — 11215.264; 21261.199; 24789.951; 21946.450…

Primary: Virological Response 4 Weeks After the End of Treatment With BI 201335 or Placebo — 0.0; 14.3; 59.7; 75.0 percentage of patients

Primary: Changes of Homocysteine Level — -0.68; -1.35 µmol/L — p=0.05

Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L

Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days

Primary: Percentage of Participants Free From Disease Progression or Death at 6 Months — 8.3; 8.1 percentage of participants

Primary: Mean Change in UPDRS III Score From Baseline in the Meds Off Condition (no Medications) to 26 Weeks Post First Lead Implantation in the Stim on/Meds Off Condition…

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — 0.05; -0.49 percentage of glycosylated haemoglobin

Primary: Difference in Minutes Between a Sacroiliac Joint Injection Done With Ultrasound vs Fluoroscopy — 9.471; 9.552 minutes

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.30; -1.32 percentage of glycosylated haemoglobin

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment — -1.17; -1.29 percentage of glycosylated haemoglobin